Accumulation of Ab peptide fragments of the APP protein and neurofibrillary tangles of the microtubule-associated protein tau are the cellular hallmarks of Alzheimer's disease (AD). To investigate the relationship between APP metabolism and tau protein levels and phosphorylation, we studied humanstem-cell-derived forebrain neurons with genetic forms of AD, all of which increase the release of pathogenic Ab peptides. We identified marked increases in intracellular tau in genetic forms of AD that either mutated APP or increased its dosage, suggesting that APP metabolism is coupled to changes in tau proteostasis. Manipulating APP metabolism by b-secretase and g-secretase inhibition, as well as g-secretase modulation, results in specific increases and decreases in tau protein levels. These data demonstrate that APP metabolism regulates tau proteostasis and suggest that the relationship between APP processing and tau is not mediated solely through extracellular Ab signaling to neurons.
Correspondence rick@gurdon.cam.ac.uk In Brief Moore et al. use neurons made from familial Alzheimer's disease stem cells to reveal how three proteins involved in the disease are linked in a pathway that controls disease progression. They show that drugs that target this pathway change levels of a protein involved in neurodegeneration, microtubuleassociated protein tau, opening up a potential therapeutic pathway.
INTRODUCTION
Accumulation of Ab peptide fragments of the APP protein and neurofibrillary tangles of the microtubule-associated protein tau are the cellular hallmarks of Alzheimer's disease (AD). However, the molecular mechanisms linking APP metabolism; extracellular Ab peptides; and changes in tau expression, phosphorylation, and cellular localization are currently unclear. Understanding of the genetics underlying monogenic familial Alzheimer's disease (fAD) has provided several insights into disease pathogenesis (Blennow et al., 2006) . The majority of known fAD mutations are autosomal dominant and affect APP or the catalytic components of the g-secretase APP-processing complex, presenilin (PSEN) 1 and 2 (Bertram and Tanzi, 2008) . Early onset AD also occurs in individuals with increased APP gene dosage due either to trisomy of chromosome 21 (Ts21) or duplication of the APP locus (APP (dup)) (Rovelet-Lecrux et al., 2006) . The identification of the mutations involved in fAD, the discovery of Ab42 as the primary component of cerebrovascular amyloid (Glenner and Wong, 1984a) and amyloid plaques (Masters et al., 1985) in late-onset sporadic AD, and the identification of the same peptide in amyloid plaques in Down syndrome (Glenner and Wong, 1984b) led to the development of the amyloid hypothesis for AD (Hardy and Allsop, 1991) .
The amyloid hypothesis postulates that accumulation of Ab42 is central to AD initiation and subsequently leads to changes in neuronal function, tau pathology, and ultimately cell death (Hardy and Allsop, 1991) . Increased production of aggregationprone Ab monomers during AD initiation results in the formation of soluble extracellular oligomers that are proposed to signal via several different specific cell surface receptors or perturb membrane integrity in a non-specific manner, resulting in neuronal dysfunction . Changes in APP processing and the generation of intracellular APP fragments have also been proposed to be involved in AD pathogenesis (Pimplikar et al., 2010) . The b-secretase-generated C-terminal fragment of APP, referred to as b-CTF or C99, has been shown to be toxic in cultured cells (Yankner et al., 1989) and cause neurodegeneration and defects in synaptic plasticity in transgenic mouse models (Lauritzen et al., 2012) . Similarly, cleavage of APP-C99 by g-secretase releases the APP intracellular domain (AICD), which is proposed to contribute to neurodegeneration (Pimplikar et al., 2010) .
We and others have previously shown that neurons generated from induced pluripotent stem cells (iPSCs) from genetic forms of AD recapitulate aspects of the disease, including increased Ab peptide production in Down syndrome (Shi et al., 2012a) and APP duplication (Israel et al., 2012) . Altered Ab40:42 ratios have also been observed in PSEN1 and APP mutant neurons (Muratore et al., 2014; Yagi et al., 2011) . Here, we investigate the relationship between APP processing and tau protein levels and phosphorylation by analysis of iPSC-derived cortical neurons with different genetic forms of AD and pharmacological manipulation of b-secretase and g-secretase. (A-C) Representative immunohistochemistry of neurons (b3-tubulin positive, blue) generated from familial Alzheimer's disease (fAD) (PSEN1 intron 4, Y115C, and APP V717I) iPSCs, expressing transcription factors restricted to layer 6 (Tbr1, red) or layer 5 (CTIP2, green) cortical projection neurons. (D) 3D nature of stem-cell-derived cortical cultures. Cultures cleared by passive CLARITY and immunostained for neurons (tau, red) and nuclei (DAPI, blue). Single-plane XY, XZ, and YZ (right, top, and left panels, respectively) projections of control neurons 100 days post-induction. The scale bar represents 100 mm. (E) Generation of Ab peptides. APP is first cleaved by b-secretase to generate membrane-bound APP-C99. This is followed by the initial g-secretase cleavage of APP-C99, termed ε-cleavage, to generate Ab peptides of either 48 or 49 amino acids. Ab peptides are then subject to sequential g-secretase carboxypeptidase cleavages, leading to extracellular release of Ab42, 40 and 38. (F) Neurons with three different PSEN1 mutations generate equivalent amounts of total extracellular Ab peptides over 40 days in culture as three different healthy control lines. APP V717I neurons also do not significantly alter the production of total Ab peptides compared to controls. This is in contrast with APP (dup) neurons, which significantly increase Ab production. Error bars, SD; n = 3 cultures for each genotype; **p < 0.01. (G) PSEN1 and APP V717I mutant neurons have significantly reduced Ab40:Ab42 ratios compared with both control and APP (dup) neurons at all time points studied, reflecting a relative increase in the generation of Ab42. Error bars, SEM; **p < 0.01.
RESULTS
Distinct Genetic Forms of Alzheimer's Disease All Increase Ab42 Generation APP processing and generation of Ab peptides in different genetic forms of AD was studied by generating cortical excitatory neurons from patient iPSCs (Shi et al., 2012c) harboring PSEN1 mutations (Y115C, M146I, and intron 4), an APP mutation (V717I), and APP duplication (APP dup ) (Israel et al., 2012; Figures 1A-1C and S1) . Over 3 months, neurons generated from monolayers of cortical progenitor cells formed dense 3D, electrically active neural networks that spanned >200 mm in thickness (Figure 1D ; Movies S1 and S2). Production of extracellular Ab peptides by neurons of each genotype was compared with that of three independent controls over the course of 90 days in culture. At all time points, PSEN1 and APP V717I neurons produced similar extracellular concentrations of the sum of Ab38, 40, and 42 peptides as healthy control neurons ( Figures 1E and 1F ). However, these mutants decreased the ratio of Ab40:Ab42 at each point assessed (Figures 1F and 1G) , reflecting an absolute and relative increase in Ab42 production compared with controls. In contrast with the other genotypes, APP dup neurons greatly overproduce Ab peptides over time, in line with increased substrate dosage (Figure 1F ), as previously found for Ts21 neurons (Shi et al., 2012a) . Overproduction of Ab peptides in APP dup neurons did not alter the relative amounts of Ab40 and Ab42 (Figures 1G and 1H) , indicating that Ab generation is limited by APP availability, rather than b-and g-secretase capacity.
Comparing relative amounts of Ab40 with the sum of Ab38 and Ab42 peptides enables inference about the initial ε-cleavage of APP-C99 by g-secretase to either Ab48 or Ab49 that are then processed in largely separate pathways ( Figure 1E ; Chá vez- Gutié rrez et al., 2012) . APP V717I neurons exhibited a significant decrease in the Ab40:Ab38+Ab42 ratio, which was not observed in APP dosage models or PSEN1 mutants ( Figure 1I ), consistent with the V717I mutation biasing the initial ε-cleavage of APP to Ab48, which is processed to both Ab42 and Ab38 ( Figure 1E ).
Multiple PSEN1 mutations resulted in a decreased Ab38:Ab42 ratio ( Figure 1J ), consistent with a hypomorphic loss of g-secretase function (Chá vez-Gutié rrez et al., 2012) . In support of this, PSEN1 mutants significantly increased the release of Ab14, Ab15, and Ab16 ( Figures 1K, 1L , and S2), which are thought to be produced by sequential cleavage of APP by b-and then a-secretase in the context of reduced g-secretase processivity (Portelius et al., 2011) . This was accompanied by a reduction in Ab40, reflecting the shift in production to shorter Ab forms (Figure 1M) , indicating that these hypomorphic PSEN1 mutations reduce g-secretase's carboxypeptidase activity.
Increased APP Gene Dosage and APP V717I Specifically Increase Neuronal Tau Protein Levels Intracellular levels of total and phosphorylated tau were increased in APP V717I and APP dup neurons, compared with controls ( Figures 2A, 2C -2E, and S3A; n = 2 independent inductions from each iPSC line). The changes in tau protein levels did not reflect an increase in the relative numbers of neurons carrying APP duplications or mutations, assessed by the levels of the neuron-specific b3-tubulin protein ( Figure 2B ). Neurons from two different PSEN1 mutations (Y115C and intron 4) did not exhibit increased total or phosphorylated tau levels, compared to controls (Figures 2A, 2C-2E, and S3A). Thus, intracellular tau levels do not correlate with the extracellular Ab40:Ab42 ratio, as PSEN1 mutant neurons exhibited a comparable ratio to APP V717I neurons (Figures 1G and 1H) . MAPT transcription was assessed by RT-PCR, demonstrating no difference in mRNA expression between neurons of each genotype ( Figure S3B ) and suggesting that the increase in tau protein observed in APP V717I and APP dup neurons is post-transcriptional and a result of altered tau proteostasis.
Pharmacological Manipulation of APP Processing Regulates Tau Proteostasis in Neurons
As PSEN1 and APP V717I mutant neurons displayed strikingly different intracellular tau protein levels but comparable levels of total extracellular Ab and Ab40:Ab42 ratios, we hypothesized that membrane-bound or intracellular products of APP processing might regulate tau proteostasis. Therefore, we compared the effects of acute g-secretase or b-secretase inhibition on tau protein levels in control neurons. As expected, inhibition of either gor b-secretase significantly reduced extracellular Ab peptides ( Figure 3A ). However, g-secretase inhibition led to an increase in tau and a marked accumulation of APP-C83/C99. Tau levels were decreased by b-secretase inhibition ( Figure 3B ), a treatment that reduces APP-C99 generation. These data indicate a link between APP processing and tau proteostasis that is regulated by g-and b-secretase activity, independent of extracellular Ab38, Ab40, and Ab42.
(H) PSEN1 and APP V717I mutant neurons exhibit a relative increase in Ab42 compared to Ab40 at day 80, whereas Ts21 and APP (dup) do not. All data produced from three independent cultures. Error bars, SD; **p < 0.01. (I) Comparing ratios of Ab40 to the sum of Ab38 and Ab42 at day 80, as an indicator of ε-cleavage and processing pathway choice, reveals that neither PSEN1 mutants nor increased APP dosage affects APP-C99 cleavage. By contrast, APP V717I mutants significantly bias the ε-cleavage APP-C99 to Ab48, which is processed to both Ab42 and Ab38. Error bars, SD. We compared the effects of the g-secretase inhibitor (GSI) DAPT with the imidazole-based g-secretase modulator E2012 (GSM) on Ts21 neurons, which exhibit increased tau protein levels and phosphorylation compared with euploid controls, providing a sensitive background on which to detect changes in tau protein. Ts21 neurons treated with DAPT over a 30-day period exhibited a dose-dependent increase in tau protein levels, accompanied by corresponding increases in APP-C83/C99 (Figures 3C and 3E ). However, g-secretase modulation resulted in a dose-dependent decrease in tau protein levels in Ts21 neurons but did not increase APP-C83/C99 ( Figures 3D and 3E ).
g-Secretase Modulation Reduces Intracellular Tau in fAD Neurons
We investigated the effect of manipulating g-secretase activity on tau proteostasis in different genetic forms of AD. To do so, we compared the effects of g-secretase inhibition and modulation on APP processing, Ab peptide production, and tau protein levels in Ts21, PSEN1, and APP V717I neurons, representing AD initiation due to increased APP copy number, reduced g-secretase carboxypeptidase processivity, and altered ε-cleavage of APP, respectively.
Inhibition of g-secretase with DAPT significantly reduced the production of extracellular Ab38, Ab40, and Ab42 in neurons of all genotypes (Figures 4A and S4A-S4C; n = 2 independent experiments for each genotype). Moreover, IP-MALDI analysis of extracellular DAPT-treated samples revealed a loss of all longer Ab peptides and a significant increase in Ab14, 15, and 16 (Figure S4E) . By contrast, E2012 reduced the absolute amount of Ab40 and Ab42 in all genotypes assessed and resulted in a marked increase of Ab37 and Ab38 ( Figures S4A-S4C and S4F ), causing increased Ab40/Ab42 and Ab38/Ab42 ratios for E2012-treated neurons, compared to vehicle controls ( Figures 4B and  4C) . Notably, E2012 treatment increased Ab40/Ab42 and Ab38/ Ab42 ratios in PSEN1 mutant neurons, demonstrating that GSMs can act on neurons carrying PSEN1 mutations. The magnitude of this effect was dependent on the nature of the mutation, with PSEN1 intron 4 mutations being least responsive to g-secretase modulation by E2012 ( Figures 4A-4D and S4A-S4C ).
In agreement with our analyses of control and Ts21 neurons, DAPT increased total tau levels and APP-C83/99 in neurons of all genotypes ( Figures 4E, 4F, and S4 ). This was accompanied by increases in site-specific phosphorylation of tau (pS202/ T205 [AT8], pS396, and pS404; Figures 4E and S4E ). E2012 significantly reduced tau protein levels and phosphorylation in neurons of each genotype, with the exception of PSEN1 intron 4 ( Figures 4E and S4G ). Ts21 neurons, which displayed the most marked changes in APP processing in response to E2012, similarly had the largest increase in both tau protein expression and phosphorylation ( Figures 4E and S4G ). Given that manipulating g-secretase could affect neurogenesis and neuronal differentiation via Notch signaling, we measured levels of neuron-specific b3-tubulin in neurons of all genotypes following treatment with GSI and GSM ( Figure 4F ). Neither drug treatment had any effect on b3-tubulin levels ( Figure 4F ) and thus did not affect neuronal number or mass.
DISCUSSION
To investigate the relationship between APP metabolism and tau protein levels and phosphorylation, we have utilized humanstem-cell-derived excitatory cortical neurons from representative genetic forms of AD with mutations in either APP or PSEN1 that are predicted to affect APP metabolism. In addition to identifying different classes of altered APP processing and Ab peptide production under physiological conditions in human forebrain neurons with different genetic forms of AD, we identified regulation of tau proteostasis by metabolism of APP. Marked increases in tau protein levels were observed in genetic forms of AD that changed APP dosage or affected the ε-cleavage site of APP. Furthermore, pharmacological manipulation of APP metabolism changed tau protein levels in human forebrain neurons in a dose-dependent manner. These findings point to a potentially important pathogenic mechanism in AD, linking APP metabolism to tau protein levels. The pathological significance of tau protein levels is clear from the small number of identified individuals with frontotemporal dementia and MAPT duplications Rovelet-Lecrux et al., 2010) .
Recent in vitro studies of AD employing overexpression of transgenes encoding mutant forms of PSEN1 and APP in human neurons or iPSC-derived APP V717I neurons have demonstrated an association between APP processing and tau pathology that is dependent on extracellular Ab peptides (Choi et al., 2014; Muratore et al., 2014) . Consistent with previous studies, we found that neurons from all fAD lines in this study led to an increase in extracellular Ab42. However, only APP duplication, Ts21, and APP V717I resulted in increased tau protein levels and phosphorylation. Elevated tau protein levels were not due to an increase in MAPT mRNA expression, suggesting a post-transcriptional mechanism.
Given the similarity in extracellular total Ab levels and specifically Ab42, among different PSEN1 and APP mutant neurons, we hypothesized that the increase in intracellular tau protein seen in a subset of genetic forms of AD may be regulated by factors in addition to extracellular Ab. As the three genotypes in which increased tau occurs either affect total APP levels (Ts21; APP duplication) or the initial ε-cleavage of APP by g-secretase (APP V717I), our studies focused on the initial intracellular processing of APP to generate APP-C83/99. Therefore, we compared the effects of b-secretase and g-secretase inhibition on APP processing and tau proteostasis in human cortical neurons. Both compounds greatly reduce extracellular Ab peptide production but at different stages of the APP-processing pathway (De Strooper, 2010) . b-secretase inhibition prevents generation of APP-C99 from full-length APP, whereas g-secretase inhibition blocks the proteolysis of APP-C83/99, resulting in accumulation of APP-C83/99. In support of a role for APP metabolism and APP-C83/99 in regulating tau levels, we found that g-secretase inhibition increased intracellular tau protein levels, whereas b-secretase inhibition reduced intracellular tau protein.
The strategy of g-secretase modulation reduced tau protein in different genetic forms of AD, suggesting that this approach to reducing tau levels may be a useful therapeutic strategy in different forms of Alzheimer's disease. The reduction in tau protein by g-secretase modulation with E2012 had differential effects depending on the specific mutation, with the degree of tau reduction correlated with the magnitude of the change in APP processing in each genotype. For example, E2012 had the most-pronounced effects on APP processing and tau levels in Ts21/Down syndrome neurons and the least effects on both APP processing and tau protein levels in PSEN1 intron 4 neurons. Finally, g-secretase modulation also reduced tau protein levels in healthy controls, indicating that the link between APP metabolism and tau proteostasis is a feature of neuronal biology in health and disease.
Overall, our data support a link between APP metabolism and tau proteostasis that is mediated by b-and g-secretase. The lack of changes in tau protein in PSEN1 mutant neurons indicates that a simple lack of carboxypeptidase processivity does not lead to altered tau proteostasis. Instead, the data reported here suggest the changes in tau levels are related to altered ε-cleavage of APP by endopeptidase activity of g-secretase and point to a possible role for APP-C99 in regulating tau proteostasis. A key question for further study is how intracellular metabolism of APP may input into controlling tau proteostasis, given the potential importance of this pathway for AD progression.
EXPERIMENTAL PROCEDURES
Generation of Familial Alzheimer's Disease iPSCs and Cerebral Cortex Neurons PSEN1 Y115C, M146I, intron 4, and APP V717I mutant fibroblasts were sourced as described (Wray et al., 2012) . Fibroblasts were reprogrammed at the Cambridge Biomedical Centre using the standard four-factor method, delivered by lentiviruses (Takahashi et al., 2007) . Each mutation was sequenced in reprogrammed clones, and pluripotency was determined by differentiation to each germ layer from embryoid bodies ( Figure S1 ). Healthy control cell lines were NDC (Israel et al., 2012) , NAS6 (Devine et al., 2011) , and the H9 ES (WiCell Research Institute); additional disease lines were APP duplication (Israel et al., 2012) and Ts21 iPSCs (Park et al., 2008) . Pluripotent cells were cultured by standard methods (see Supplemental Information for details).
Directed differentiation of hESCs and iPSCs to cerebral cortex was carried out as described, with minor modifications (Shi et al., 2012b, c) . For drug treatment, all compounds were dissolved in DMSO at the concentrations noted, and DMSO was the vehicle control in all experiments. Compounds were added every 48 hr during treatment period: g-secretase inhibitor, DAPT (Sigma); gsecretase modulator, E2012 (ChemExpress); and b-secretase inhibitor LY2886721 (Selleck).
Immunocytochemistry and Imaging
Fixed and immunostained cultures were imaged on an Olympus FV1000 inverted confocal microscope (see Supplemental Information for details). For Figure 4 . Manipulation of g-Secretase Activity Alters Ab Peptide Production, Tau Expression, and Phosphorylation Status in Genetic Forms of AD (A) DAPT (GSI) prevents the production of Ab38, Ab40, and Ab42 observed in DMSO-treated controls (Ctrl). In contrast, E2012 (GSM) reduces total Ab peptide production by approximately one third. All compounds used at 1 mM and extracellular media analyzed at day 80 post-neural induction, after 20 days of drug treatment. Error bars, SD. Neurons of each genotype are as marked; n = 3 cultures for each treatment group; **p < 0.01. (B-D) Changes in relative Ab peptide production in response to each compound are reflected in the ratios between the different Ab species. E2012 (GSM) has particularly marked effects in reducing the concentration of Ab42 relative to Ab40 (B) and in increasing the concentration of Ab38 relative to Ab42 (C). Error bars, SD; **p < 0.01. (E) Western blots performed on soluble protein extracts of neurons following treatment with the indicated compounds. Protein extraction performed at day 90 post-neural induction, after 30 days of drug treatment. DAPT treatment (GSI) increases both total and phosphorylated tau expression in the majority of genotypes, assessed at multiple epitopes. By contrast, E2012 (GSM) reduces total tau expression and its phosphorylation in all genotypes assayed, with particularly pronounced effects in Ts21 neurons. Error bars, SD; n = 2 for each treatment group; representative western blots shown, with additional data in Figure S4 . (F) GSI with DAPT increased APP-C83/99 in neurons of all genotypes, with differing efficacy in some PSEN1 mutants, whereas GSM (E2012) had no effect on APP-C83/99. Drug treatments had no effect on neuronal number, as reflected in the amount of neuron-specific b3-tubulin.
optical clearing, fixed cultures were processed according to the method described (Yang et al., 2014) .
Protein Analysis
Quantification of Ab42, Ab40, and Ab38 were carried out with multiplexed MesoScale Discovery assay kits on a Quickplex SQ120 instrument (MesoScale Discovery) using 25 ml of cell culture supernatant. All statistical comparisons were between the entire set of controls samples and all samples of each genotype, using Student's t test with the Bonferroni correction for multiple testing. Three independent cultures of neurons derived from each clone were used for all measurements, except where noted. Cellular protein extraction and western blot analysis were carried out as described (Supplemental Information).
IP-MALDI Analysis of Ab Peptides IP of cell media was performed using a KingFisher magnetic particle processor (Thermo Scientific) as described (Portelius et al., 2007) . See Supplemental Information for further details. 
Pluripotent stem cell culture
Pluripotent stem cells were maintained on mouse embryonic fibroblasts (MEFs) (GlobalStem) in DMEM/F12 containing 20% KSR (vol/vol), 100 µm non-essential amino acids, 100 µM 2-mercaptoethanol, 50 U ml −1 penicillin and 50 mg ml −1 streptomycin (all Life Technologies) and 10 ng ml −1 FGF2.
Immunostaining and imaging
Cultures were fixed in 4% paraformaldehyde in phosphate buffered saline or methanol at -20°C before being processed for immunofluorescence staining and confocal microscopy.
Antibodies used for immunofluorescence in this study were Tbr1 (Abcam, ab31940), CTIP2 (Abcam, ab18465), β3-tubulin (Covance, MMS-435P), and total tau (Dako Cytomation, A0024).
Calcium imaging
Calcium imaging was performed on familial AD (PSEN1 Y115C, Intron 4 and APPV717) and control (NDC) cultures aged between 8 and 9 weeks post-induction.
Cells were loaded with the calcium indicator Oregon Green 488 BAPTA (OGB) by diluting a 0.7mM OGB stock solution to 3.2µM in N2B27 media containing 0.01% v/v
Cremaphor EL and 0.4% Pluronic F-127 to make a loading solution. Cells were then bathed in the OGB loading solution for 1 hour at 37ºC and 7% CO 2 in the dark. The loading solution was then removed and the cells were washed over twice with N2B27 and incubated for a further 30 minutes at 37ºC and 7% CO 2 in the dark in N2B27. The cells were then imaged in artificial CSF using a Deltavision (Applied Precision), with an EMCCD camera and using softWoRx 5.0.0 (Applied Precision) software. The imaging chamber was heated to 37ºC and supplied with 5% CO 2 . The recordings were 2 minutes in length and were captured at 10 Hz. The 2-minute movies were converted to AVI format playing at 150 frames per second using ImageJ software.
supernatant was dried in a vacuum centrifuge and redissolved in 5 µL 0.1% formic acid in 20% acetonitrile. Samples were analyzed by MALDI TOF/TOF (Autoflex, Bruker
Daltonics, Bremen, Germany) operating in reflector mode. FlexAnalysis (version 3.3, Bruker Daltonics) was used for automated integration of the peaks for each spectrum.
Prior to the statistical analysis, the peak areas were normalized to the sum of the integrated peaks, duplicated samples were averaged, and the relative changes compared to baseline values were calculated. All solvents used were of HPLC quality.
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